Peer-Reviewed Journal Details
Mandatory Fields
Chaccour, C. J.,Ngha'bi, K.,Abizanda, G.,Irigoyen Barrio, A.,Aldaz, A.,Okumu, F.,Slater, H.,Del Pozo, J. L.,Killeen, G.
2018
May
Parasit Vectors
Targeting cattle for malaria elimination: marked reduction of Anopheles arabiensis survival for over six months using a slow-release ivermectin implant formulation
Validated
Optional Fields
Cattle Endectocides Ivermectin Pharmacokinetics Residual transmission Slow release Zoophagy
11
1
287
BACKGROUND: Mosquitoes that feed on animals can survive and mediate residual transmission of malaria even after most humans have been protected with insecticidal bednets or indoor residual sprays. Ivermectin is a widely-used drug for treating parasites of humans and animals that is also insecticidal, killing mosquitoes that feed on treated subjects. Mass administration of ivermectin to livestock could be particularly useful for tackling residual malaria transmission by zoophagic vectors that evade human-centred approaches. Ivermectin comes from a different chemical class to active ingredients currently used to treat bednets or spray houses, so it also has potential for mitigating against emergence of insecticide resistance. However, the duration of insecticidal activity obtained with ivermectin is critical to its effectiveness and affordability. RESULTS: A slow-release formulation for ivermectin was implanted into cattle, causing 40 weeks of increased mortality among Anopheles arabiensis that fed on them. For this zoophagic vector of residual malaria transmission across much of Africa, the proportion surviving three days after feeding (typical mean duration of a gonotrophic cycle in field populations) was approximately halved for 25 weeks. CONCLUSIONS: This implantable ivermectin formulation delivers stable and sustained insecticidal activity for approximately 6 months. Residual malaria transmission by zoophagic vectors could be suppressed by targeting livestock with this long-lasting formulation, which would be impractical or unacceptable for mass treatment of human populations.
1756-3305 (Electronic) 17
https://www.ncbi.nlm.nih.gov/pubmed/29728135
10.1186/s13071-018-2872-y
Grant Details